⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2366310 | 1.00 | — | — | |
| SCHEMBL2366306 | 1.00 | — | — | |
| Hydrochloric Acid SCHEMBL6081445 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL6081448 | 0.97 | — | — | |
| Hydrochloric Acid SCHEMBL17957617 | 0.97 | — | — | |
| SCHEMBL509933 | 0.81 | — | — | |
| SCHEMBL4324237 | 0.79 | — | — | |
| SCHEMBL8211403 | 0.78 | — | — | |
| SCHEMBL8408267 | 0.78 | — | — | |
| SCHEMBL5318401 | 0.78 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 63 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2592070-B1 | Tetrazole-substituted arylamides | HOFFMANN LA ROCHE (CH) | 2016-08-31 | — | — | EP | claimed |
| EP-2592070-A2 | Tetrazole-substituted arylamides | F. Hoffmann-La Roche AG (CH) | 2013-05-15 | — | — | EP | claimed |
| US-20260098036-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-04-09 | — | — | US | disclosed |
| US-12522594-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | DEUTSCHES KREBSFORSCHUNGSZENTRUM (DE) | 2026-01-13 | — | — | US | disclosed |
| US-12473295-B2 | Substituted straight chain spiro derivatives | JANSSEN PHARMACEUTICA NV (BE) | 2025-11-18 | — | — | US | disclosed |
| US-20250034120-A1 | PYRIDAZINONES AS PARP7 INHIBITORS | RIBON THERAPEUTICS, INC. | 2025-01-30 | — | — | US | disclosed |
| US-20240294505-A1 | 2-HETEROARYL-3-OXO-2,3-DIHYDROPYRIDAZINE-4-CARBOXAMIDES FOR THE TREATMENT OF CANCER | BAYER AKTIENGESELLSCHAFT (DE) | 2024-09-05 | — | — | US | disclosed |
| US-20230357510-A1 | RAPID-CURING TWO-COMPONENT SILICONE COMPOSITION HAVING A LONGER MIXER OPEN TIME | SIKA TECHNOLOGY AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-20230357510-A1 | RAPID-CURING TWO-COMPONENT SILICONE COMPOSITION HAVING A LONGER MIXER OPEN TIME | SIKA TECHNOLOGY AG (CH) | 2023-11-09 | — | — | US | disclosed |
| US-11795164-B2 | 2-heteroaryl-3-oxo-2,3-dihydropyridazine-4-carboxamides for the treatment of cancer | BAYER AKTIENGESELLSCHAFT (DE) | 2023-10-24 | — | — | US | disclosed |
| EP-4234551-A2 | PYRIDAZINONES AS PARP7 INHIBITORS | Ribon Therapeutics Inc. (US) | 2023-08-30 | — | — | EP | disclosed |
| US-20120172321-A1 | HSP90 INHIBITORS | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-07-05 | — | — | US | disclosed |
| US-8193368-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2012-06-05 | — | — | US | disclosed |
| US-20100022476-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2010-01-28 | — | — | US | disclosed |
| US-20090326220-A1 | Tetrazole-Substituted Arylamides as P2X3 and P2X2/3 Antagonists | DILLON MICHAEL PATRICK | 2009-12-31 | — | — | US | disclosed |
| US-7595405-B2 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC (US) | 2009-09-29 | — | — | US | disclosed |
| US-20080004442-A1 | Tetrazole-substituted arylamides as P2X3 and P2X2/3 antagonists | ROCHE PALO ALTO LLC | 2008-01-03 | — | — | US | disclosed |
| WO-2007133756-A2 | CRF1 RECEPTOR LIGANDS COMPRISING HETEROARYL FUSED BICYCLES | NEUROGEN CORPORATION (US) | 2007-11-22 | — | — | WO | disclosed |
| EP-1836191-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | AstraZeneca AB (SE) | 2007-09-26 | — | — | EP | disclosed |
| WO-2006067391-A1 | PYRAZOLYLAMINO SUBSTITUTED QUINAZOLES FOR THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2006-06-29 | — | — | WO | disclosed |